RBC Capital Markets has published its quarterly global stock selection list for 2026, featuring 30 high-conviction equity ideas. The update, led by Co-Heads of Global Research Graeme Pearson and Mark Odendahl, retains 27 positions from the prior quarter while introducing three new names and removing three others.
The additions to the Top 30 list are Apotex Health, Canadian National Railway and Lonza. Removed from the roster are Alcon, Boston Scientific and DuPont de Nemours, as the bank prioritized higher-conviction selections. Canadian National Railway, operating across industrials and healthcare segments, reported adjusted earnings of C$2.08 per share on revenue of $4.75 billion in Q2 2026, topping estimates and prompting upward revisions to full-year guidance. Evercore ISI raised its price target for the company, while Benchmark maintained a Hold rating.
Apotex Health holds a 23% share in the Canadian generic drug market and ranks among the top-10 players in the U.S. generic pharmaceutical sector. Lonza, positioned within healthcare and industrials, is cited as an earnings-per-share compounder trading at a valuation that the bank views as attractive relative to its growth prospects.
Over the second quarter of 2026, the Top 30 list generated a total return of 11.1% in U.S. dollar terms, underperforming the MSCI World Index’s 12.8% gain during the same period. Since its inception at year-end 2019, the portfolio has delivered a compound annual return of 13.9%, outpacing the benchmark’s 13.4% return over the same horizon.
